ETH-LAD (6-ethyl-6-nor-lysergic acid diethylamide) is a semi-synthetic psychedelic of the lysergamide family that occupies a strange position in the psychedelic landscape: more potent than LSD by weight, more visually intense by virtually every account, shorter in duration, and yet far less popular. The reason is its body. ETH-LAD hits the body harder than almost any other lysergamide, producing nausea, muscle tension, and a vasoconstriction-heavy physical load that colors the entire experience. People who love it describe visuals that surpass LSD in crystalline sharpness and geometric complexity. People who don't love it describe two hours of nausea followed by four hours of wondering whether the visuals were worth the stomach cramps. Both groups are accurately reporting the same substance.
The compound was first synthesized by Niwaguchi and colleagues in Japan in 1976 and subsequently characterized in behavioral pharmacology studies by Andrew Hoffman and David Nichols at Purdue University in 1985. It is entry number 12 in Alexander Shulgin's TiHKAL (Tryptamines I Have Known and Loved). The structural modification is subtle -- replacing LSD's N6-methyl group with an ethyl group -- but the pharmacological consequences are significant. Binding studies show a Ki of 5.1 nM at the serotonin 5-HT2A receptor (very high affinity, comparable to or exceeding LSD) and unusually strong affinity for dopamine D1 and D2 receptors, which likely accounts for the pronounced physical stimulation and body load that distinguish ETH-LAD from its parent compound.
ETH-LAD appeared on the research chemical market around 2015 and attracted immediate attention for its reputation as the "visual lysergamide." At doses of 100-150 µg, users report visual effects that rival or surpass 200+ µg of LSD: surfaces shatter into crystalline geometries, closed-eye imagery is dense and architecturally complex, and colors achieve a hyper-defined sharpness that people describe as "digital" or "electric." The headspace, conversely, is often reported as somewhat less overwhelming than LSD at equivalent visual intensity -- present, confusing, and emotionally intense, but with less of LSD's characteristic philosophical weight. Duration runs 6-10 hours, shorter than LSD's typical 8-12.
The compound demands respect in a way that LSD does not. ETH-LAD has a steep dose-response curve, meaning the difference between a comfortable experience and an overwhelming one can be 25-50 µg. The body load is not a footnote; it is a defining feature. And the relative scarcity of human data compared to LSD means there are genuine unknowns. ETH-LAD rewards careful dosing and thorough preparation, and it punishes cavalier approaches more harshly than most lysergamides.
Safety at a Glance
High Risk- Dosing -- This Is Not LSD
- Threshold: 15-40 µg
- Toxicity: Acute Toxicity ETH-LAD has no documented fatal overdoses in the medical or forensic toxicology literature. Like other...
- Overdose risk: Can You Overdose on ETH-LAD? A pharmacologically fatal overdose on ETH-LAD is extremely unlikely ...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 8 hrs – 12 hrsHow It Feels
The body announces ETH-LAD before the mind has any say in the matter. Within fifteen to twenty minutes of placing the tab under your tongue, a spreading heaviness settles into the abdomen -- not pain exactly, but a dense, uncomfortable tightness that wraps around the stomach and presses into the lower back. Nausea follows, rolling in waves. It is not always severe, but it is persistent, and it colors the early experience with an endurance quality that LSD simply does not have. The muscles begin to tighten: jaw clenching, tension in the shoulders, a buzzing electric current through the limbs as though every nerve is running slightly too hot. Some people describe it as being plugged into a wall socket at low voltage. This is not a gentle come-up.
Then the visuals arrive, and they arrive with an authority that justifies the physical cost of admission. ETH-LAD is among the most visually intense substances in the entire lysergamide family, and this is not subtle community consensus -- it is near-universal agreement. Surfaces do not merely breathe and ripple as they do on LSD. They shatter. Geometric patterns fracture across every surface with a crystalline, sharp-edged precision that people consistently describe as "digital" or "hyper-defined." Colors reach a saturation that feels almost physically impossible, as though the visual cortex has been overclocked. Closed-eye imagery is staggeringly dense: towering architectural structures of light, rotating geometric machinery, fractal cathedrals that evolve with a mechanical precision quite unlike the organic flowing of LSD or psilocybin visuals. The contrast between the visual magnificence and the physical discomfort is the central tension of the ETH-LAD experience -- you are seeing some of the most beautiful things a psychedelic can show you while your stomach is actively protesting.
The headspace is confusing in a way that is distinct from LSD. Where LSD tends toward expansive philosophical insight, ETH-LAD fragments thought in a more angular, disoriented fashion. Linear reasoning becomes genuinely difficult. Thoughts arrive in shards rather than streams, recombining in unexpected and sometimes bewildering ways. Time perception warps severely -- minutes stretch into what feel like hours, and there are jarring moments where time seems to fold back on itself. Emotional responses are intense and switch rapidly, from awe to anxiety to hilarity with almost no transition between them. At higher doses the sense of self becomes uncertain, but this dissolution has a different texture from LSD or mushroom ego loss -- it is more crystalline, more angular, less oceanic. People describe it as being shattered rather than dissolved.
The shorter duration is, for many users, the saving grace. By five to six hours the peak has clearly broken. The physical tension begins to release -- the stomach settles, the muscles unclench, the jaw loosens. Visual intensity softens from its peak sharpness into gentle, residual patterning. The emotional turbulence subsides into something quieter and more reflective. The afterglow carries a particular quality: exhausted wonder, the feeling of having been shown something extraordinary through a window that was physically uncomfortable to look through. There is often residual muscle soreness, a strong desire for food and rest, and a deep appreciation for the ordinary. Sleep, when it finally comes, tends to be heavy and restorative.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(24)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Mouth numbing— Mouth numbing is a localized loss of sensation in the tongue, gums, cheeks, and surrounding oral tis...
- Muscle cramp— Muscle cramps are sudden, involuntary, and often painful contractions of muscles that occur as a sid...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
- Watery eyes— Excessive tear production causing overflow tearing and blurred vision, commonly occurring during opi...
Cognitive & Perceptual Effects
Visual(19)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Environmental patterning— A visual effect in which existing textures and surfaces — carpets, clouds, foliage, walls — spontane...
- External hallucination— A visual hallucination that manifests within the external environment as though it were physically r...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(25)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Language suppression— A diminished ability to formulate, comprehend, or articulate language, ranging from difficulty findi...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Multiple thought streams— The experience of having more than one internal narrative or stream of consciousness simultaneously ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Panic attack— A panic attack is a discrete episode of acute, overwhelming fear or terror that arises suddenly and ...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Thought organization— Enhanced ability to structure, categorize, and systematize thoughts and ideas, common with low-dose ...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(4)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(5)
- Gustatory hallucination— Gustatory hallucinations are phantom taste experiences in which distinct flavors manifest in the mou...
- Machinescapes— Machinescapes are complex multisensory hallucinations involving the perception of enormous mechanica...
- Olfactory hallucination— Olfactory hallucinations (phantosmia) involve the perception of convincing phantom smells — pleasant...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(4)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
ETH-LAD acts directly as a potent agonist at the serotonin 5-HT2A receptor, the principal molecular target for classical psychedelic effects. Unlike 1P-LSD or other N1-acyl prodrugs, ETH-LAD is not converted into LSD -- it is active in its own right. Binding studies report a Ki of 5.1 nM at 5-HT2A, indicating extremely high affinity that is comparable to or greater than LSD itself. This direct activity, combined with the structural changes at the N6 position, produces a pharmacological profile that overlaps with LSD but is distinctly its own.
Receptor Binding Profile
ETH-LAD's receptor affinities differ meaningfully from LSD in ways that likely explain the subjective differences users report:
- 5-HT2A receptors -- Primary psychedelic target. Ki = 5.1 nM. The high affinity at this receptor, combined with whatever downstream signaling bias the ethyl substitution introduces, likely accounts for ETH-LAD's reputation as the most visually intense common lysergamide
- Dopamine D1 receptors -- Ki = 22.1 nM. Notably higher affinity than LSD
- Dopamine D2 receptors -- Ki = 4.4 nM. Remarkably high affinity, substantially greater than LSD's D2 binding. This broad dopaminergic activity is unusual among classical psychedelics and likely contributes to the pronounced stimulant-like body load, the physical tension, and the characteristic "wired" quality of the ETH-LAD experience
- 5-HT2C, 5-HT2B, 5-HT1A receptors -- Expected lysergamide-class activity, though comprehensive selectivity profiling specific to ETH-LAD remains limited
The combination of extremely high 5-HT2A affinity (driving visual intensity) with strong dopaminergic activity (driving somatic effects) is the likely pharmacological basis for ETH-LAD's signature profile: spectacular visuals paired with difficult body load.
Potency
Drug discrimination studies by Hoffman and Nichols (1985) confirmed ETH-LAD's psychedelic profile using rats trained to recognize LSD. Animals generalized completely to ETH-LAD at doses indicating 1.6 to 2.3-fold higher potency relative to LSD on a weight basis. This is consistent with user reports that effective doses are lower: 100 µg of ETH-LAD produces effects comparable to 150-200 µg of LSD in visual intensity, while the overall experience is qualitatively different.
Metabolism
In vitro studies have identified five ETH-LAD metabolites formed through multiple enzymatic pathways. CYP3A4 mediates N6-dealkylation (removal of the ethyl group) and N-deethylation, while CYP2D6 and CYP3A4 together catalyze various hydroxylation reactions. ETH-LAD shows greater metabolic stability in vitro compared to N1-acyl-substituted lysergamide prodrugs, consistent with its direct activity -- the molecule does not need to be converted to work, and it resists metabolic breakdown more effectively than its prodrug cousins.
Structure-Activity Context
Within Nichols' systematic exploration of N6-substituted norlysergic acid derivatives, the ethyl group represents an optimal small alkyl substitution: large enough to meaningfully alter the binding profile (increasing both potency and dopaminergic activity), small enough to maintain high 5-HT2A affinity. Larger N6 substituents (propyl, allyl) showed declining affinity and behavioral potency, making ethyl the sweet spot for this structural position.
Tolerance
Rapid tolerance within 24-48 hours, as with all serotonergic psychedelics. Complete cross-tolerance with LSD, psilocybin, mescaline, and other classical psychedelics. Baseline sensitivity returns in approximately 5-7 days.
Detection Methods
Urine Detection
ETH-LAD and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.
Blood and Serum Detection
Blood detection windows for ETH-LAD are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.
Standard Drug Panel Inclusion
ETH-LAD is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.
Confirmatory Methods
When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Ehrlich reagent is the primary tool for ETH-LAD. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Synthesis and Academic Origins (1976-1985)
ETH-LAD was first synthesized by Niwaguchi and colleagues in Japan in 1976 as part of a systematic investigation of norlysergic acid derivatives. The work was published in Yakugaku Zasshi and represented one of several structural explorations of the lysergamide scaffold during that era. The compound was subsequently taken up by Andrew Hoffman and David Nichols at Purdue University, whose 1985 paper in the Journal of Medicinal Chemistry established its psychedelic potency through drug discrimination studies in LSD-trained rats. Nichols' work demonstrated that the N6-ethyl substitution produced a compound 1.6-2.3 times more potent than LSD by weight, with full generalization to LSD's discriminative stimulus -- meaning trained animals could not distinguish its pharmacological signature from LSD's.
TiHKAL Entry #12 (1997)
ETH-LAD is entry number 12 in Alexander and Ann Shulgin's 1997 book TiHKAL: Tryptamines I Have Known and Loved. Shulgin's notes describe a compound with intense visual effects, significant body load, and a somewhat shorter duration than LSD. The Shulgins tested it at doses from 40 to 150 µg and noted the steep dose-response curve -- a characteristic that community reports would later confirm extensively. Shulgin described the visual effects as among the most intense of the lysergamide derivatives he explored.
Research Chemical Market Appearance (2015)
ETH-LAD became commercially available through online research chemical vendors around 2015, part of the same wave that brought 1P-LSD, AL-LAD, and other Shulgin-documented lysergamides to the consumer market. It was sold primarily as blotter paper and attracted a dedicated following among psychonauts specifically interested in the visual dimension of the psychedelic experience. The research chemical market provided the first large-scale human experiential dataset for ETH-LAD, supplementing the limited academic literature with thousands of trip reports documenting dose-response relationships, body load characteristics, and subjective comparisons with LSD and AL-LAD.
Analytical Characterization (2017)
Brandt et al. published the first comprehensive analytical characterization of ETH-LAD in 2017 as part of the "Return of the lysergamides" series in Drug Testing and Analysis. This paper provided chromatographic and mass spectrometric profiles for both ETH-LAD and its propionylated derivative 1P-ETH-LAD, along with in vitro metabolism data identifying five metabolites and the cytochrome P450 enzymes responsible for their formation.
Regulatory Status
ETH-LAD has been explicitly scheduled or captured under analog legislation in several jurisdictions including Germany (NpSG, 2019), Switzerland (Verzeichnis E, 2015), Latvia (LSD analog amendment, 2015), Poland (NPS classification), Turkey, and the United Kingdom (Psychoactive Substances Act, 2016). In many other countries it remains in a legal grey area -- not specifically scheduled but potentially prosecutable under analog statutes. Its availability has fluctuated as vendors and regulators have shifted attention to newer lysergamide analogs.
Harm Reduction
Test It
Ehrlich reagent: purple or violet confirms an indole compound and rules out the most dangerous blotter-active substitutes (NBOMe, DOx). A Hofmann reagent (blue) provides secondary confirmation. If there is no Ehrlich reaction, it is not a lysergamide and should not be taken.
Dosing -- This Is Not LSD
ETH-LAD is more potent than LSD by weight (1.6-2.3x in preclinical studies) and has a significantly steeper dose-response curve. The margin between a comfortable experience and an overwhelming one is narrower than with LSD. This makes accurate dosing critically important:
- Threshold: 15-40 µg
- Light: 40-75 µg
- Common: 75-125 µg
- Strong: 125-200 µg
- Heavy: 200+ µg (not recommended -- body load and psychological intensity escalate sharply)
First-timers: 50-75 µg. Even experienced LSD users should start at the low end of the common range. The body load at higher doses can transform a visual masterpiece into a physical ordeal. Do not apply your LSD dose expectations to ETH-LAD.
Managing the Body Load
The nausea and physical discomfort are not a sign that something is wrong -- they are a characteristic feature of the compound. Strategies that help:
- Ginger (capsules, tea, or candied) taken 30-60 minutes before dosing reduces nausea for many users
- Light stomach: dose on a light meal eaten 2-3 hours prior, not on a full or empty stomach
- Magnesium supplementation may help with muscle tension and jaw clenching
- Movement: gentle walking or stretching can alleviate the feeling of physical tightness more than sitting still
- Accept that some body load is part of the experience. Fighting it tends to amplify anxiety
Set and Setting
Everything that applies to LSD applies here with additional emphasis:
- Mindset: Stable emotional state is essential. ETH-LAD's confused, fragmented headspace is harder to navigate than LSD's if you start from a bad place
- Environment: Comfortable, familiar, low-stimulation. Nature works well but ensure you have a comfortable place to sit or lie down if nausea peaks
- Trip sitter: More important than with LSD, especially above 100 µg. The combination of physical discomfort and cognitive confusion can be disorienting enough that an anchor person makes a significant difference
- Plan for 8-10 hours including afterglow, even though the active phase may be shorter
Dangerous Combinations
- Lithium -- Absolute contraindication. Seizure and cardiac risk with all lysergamides
- MAOIs -- Serotonin syndrome risk
- Tramadol -- Lowers seizure threshold
- Cannabis -- Dramatically amplifies both the visual intensity and the body load. Given that ETH-LAD's body load is already its primary challenge, cannabis is particularly risky here
- Stimulants -- ETH-LAD already has significant dopaminergic activity. Adding stimulants compounds cardiovascular strain and physical tension
- Alcohol -- Worsens nausea and impairs judgment during an already cognitively demanding experience
If Things Get Difficult
- Change the environment, reduce stimulation, change or stop the music
- For nausea: try ginger ale, lie on your side, cold cloth on the back of the neck
- Grounding: cold water on face and wrists, slow breathing, physical contact with a trusted person
- Reassurance: "This is a substance. It will end. The body discomfort is normal and temporary"
- Benzodiazepines (diazepam 10-20 mg) reliably reduce both psychological intensity and some of the physical tension
Toxicity & Safety
Acute Toxicity
ETH-LAD has no documented fatal overdoses in the medical or forensic toxicology literature. Like other classical lysergamides, it is expected to have an extremely high therapeutic index -- the lethal dose is almost certainly orders of magnitude above any psychoactive dose. However, ETH-LAD stands apart from LSD and most other lysergamides in producing more frequent and more pronounced adverse physical effects at psychoactive doses.
The Body Load Problem
ETH-LAD's somatic toxicity profile is its distinguishing feature and the primary reason it requires separate safety consideration from LSD:
- Nausea and vomiting -- Reported with considerably greater frequency and severity than LSD. During the onset period (20-60 minutes), nausea can be intense enough to cause vomiting, which typically resolves as peak psychedelic effects emerge. This is the most commonly cited negative aspect in community reports
- Vasoconstriction -- Peripheral vasoconstriction manifests as cold extremities, physical tightness, numbness or tingling in fingers and toes. Reported more commonly with ETH-LAD than with LSD or AL-LAD, likely related to serotonergic and dopaminergic activity in vascular smooth muscle
- Muscle tension and bruxism -- Jaw clenching, generalized muscle tension, and a heavy uncomfortable body sensation are frequently described, particularly above 100 µg. The dopaminergic component (D1/D2 activity) likely contributes to this somatic profile
- Cardiovascular effects -- Tachycardia and blood pressure elevation are expected serotonergic psychedelic class effects but may be more pronounced with ETH-LAD given its broader receptor profile, particularly the strong D2 binding
The Steep Dose-Response Curve
ETH-LAD's dose-response relationship is notably steeper than LSD's. The practical consequence: the difference between "manageable body load with great visuals" and "severe nausea with overwhelming intensity" can be as little as 25-50 µg. This makes dosing errors more consequential per microgram than with LSD and is a significant safety consideration, especially given the lack of standardized potency data for research chemical blotters.
Psychological Risks
The same psychological risks that apply to all classical psychedelics apply to ETH-LAD, potentially amplified by the physical discomfort:
- Acute panic and anxiety -- Physical discomfort can feed psychological distress in a reinforcing loop: nausea triggers anxiety, anxiety amplifies nausea
- Psychosis precipitation -- Absolute contraindication with personal or family history of schizophrenia or bipolar I disorder
- HPPD -- Persistent visual disturbances have been reported; ETH-LAD's intense visual profile may carry particular risk, though data are insufficient to confirm this
- Cognitive confusion -- The fragmented, disoriented headspace can be particularly challenging for people who need a sense of control
Risk Populations
Individuals with cardiovascular conditions, Raynaud's phenomenon, or vascular disorders face elevated risk from the vasoconstriction. People with gastrointestinal sensitivity or conditions like IBS may find the nausea and abdominal effects particularly difficult. The higher potency means that people accustomed to LSD dosing conventions may inadvertently take more than intended.
Long-Term Toxicity
No formal studies have evaluated the long-term toxicity of ETH-LAD. By analogy with LSD, significant chronic organ toxicity seems unlikely, but this remains unestablished for ETH-LAD specifically. The rapid tolerance mechanism limits use frequency, which reduces cumulative exposure.
Addiction Potential
ETH-LAD is not addictive, and if anything, the nature of the experience actively discourages repeated use. The pronounced body load -- nausea, muscle tension, vasoconstriction -- means that even people who deeply value the visual experience often space their use widely, not because of tolerance concerns but because their body needs time to recover from the physical demands. Like all classical psychedelics, ETH-LAD produces no physical dependence, no withdrawal syndrome, and no compulsive drug-seeking behavior. Laboratory animals refuse to self-administer LSD and related lysergamides, which is one of the strongest preclinical indicators of low abuse liability. Rapid tolerance within 24-48 hours makes consecutive-day use essentially pointless, and complete cross-tolerance with all serotonergic psychedelics prevents substitution patterns. ETH-LAD's particular combination of high visual reward and high physical cost creates what community members sometimes call a "built-in regulator" -- the experience is intense enough that most users naturally wait weeks to months between sessions, and many describe it as a substance they are glad to have experienced but do not feel any pull to revisit frequently. Problematic patterns of psychological reliance are possible in theory, as with any psychedelic, but are vanishingly rare with ETH-LAD specifically.
Overdose Information
Can You Overdose on ETH-LAD?
A pharmacologically fatal overdose on ETH-LAD is extremely unlikely given the high therapeutic index of classical lysergamides. However, ETH-LAD is notably less forgiving than LSD at high doses. Community reports are consistent: overdose-range effects with ETH-LAD begin at doses that would be merely "strong" for LSD, and the experience is described as significantly more physically and psychologically punishing than a comparable LSD overdose.
What High-Dose ETH-LAD Looks Like
Above 200 µg (and sometimes lower, depending on individual sensitivity):
- Severe nausea and vomiting -- Often intense enough to dominate the experience for the first 1-2 hours
- Extreme muscle tension -- Full-body rigidity, painful jaw clenching, cramping
- Intense vasoconstriction -- Cold, numb extremities, feelings of dangerous tightness
- Overwhelming visual intensity -- Visual field completely overtaken by geometric hallucinations, loss of contact with physical surroundings
- Severe cognitive confusion -- Inability to form coherent thoughts, complete disorientation in space and time
- Acute panic and paranoia -- The combination of physical distress and cognitive confusion creates a particularly difficult spiral
- Rare: seizures -- Documented in community reports at high doses, though this may reflect adulterant contamination in some cases
Recognizing When to Call for Help
Seek immediate medical attention for:
- Seizures of any kind
- Hyperthermia -- Dangerously elevated body temperature
- Persistent vomiting with inability to keep fluids down (dehydration risk)
- Signs of serotonin syndrome if other serotonergic substances were combined: rigidity, rapid temperature rise, confusion, clonus
- Complete unresponsiveness or catatonia
- Self-harm behavior or suicidal statements
What To Do
For someone in psychological distress without medical emergency:
- Move to a calm, low-stimulation environment. Lying on one's side helps if nausea is severe
- Provide steady, calm reassurance: "This is ETH-LAD. The body discomfort is normal for this substance. It will pass. You are safe"
- Cold cloth on the back of the neck for nausea; cold water on wrists for grounding
- Do not leave a distressed person alone
- Benzodiazepines (diazepam 10-20 mg) are the first-line intervention for both psychological distress and some of the physical tension. They do not interact dangerously with lysergamides
For medical emergencies: call emergency services immediately. Good Samaritan laws protect callers in most jurisdictions. Inform responders that a lysergamide psychedelic was taken. Treatment is supportive: IV fluids, antiemetics, benzodiazepines for agitation and seizures, cooling for hyperthermia.
After a Difficult ETH-LAD Experience
The physical component of a difficult ETH-LAD experience can leave lasting somatic impressions -- muscle soreness, residual nausea, body tension that takes a day or two to fully resolve. Talk through the experience with someone you trust. If psychological symptoms (anxiety, depersonalization, visual disturbances) persist beyond a few weeks, seek professional help.
Tolerance
| Full | almost immediately after ingestion |
| Half | 5-7 days |
| Zero | 14 days |
Cross-tolerances
Legal Status
ETH-LAD is currently a gray area compound within many parts of the world. This means that it is not known to be specifically illegal within most countries. People may still be charged for its possession under certain circumstances such as under analogue laws (as an analogue of LSD) and with the intent to sell or consume.
Austria: ETH-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
Germany: ETH-LAD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Latvia: ETH-LAD is illegal in Latvia. Although ETH-LAD is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
Poland: ETH-LAD is a NPS class drug in Poland, making it illegal to possess or distribute.
Switzerland: ETH-LAD is a controlled substance specifically named under Verzeichnis E.. It is scheduled as of the of December 1, 2015.
Turkey:** ETH-LAD is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: As of January 7, 2015, ETH-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A controlled substance.
United States: ETH-LAD is unscheduled in the United States. It may be considered an analogue of LSD (which is a Schedule I compound under the Controlled Substances Act). As such, the sale for human consumption or the use for illicit non-medical or scientific research could be prosecuted as crimes under the Federal Analogue Act.
Responsible use (Hallucinogens)
Research chemical
Psychedelic
Lysergamide
LSD
ETH-LAD (Wikipedia)
ETH-LAD (TiHKAL / Isomer Design)
Discussion
The Big & Dandy ETH-LAD Thread (Bluelight)
Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255. https://doi.org/10.1021/jm00147a022.
Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409. https://doi.org/10.1007/BF02245940.
Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.
Experience Reports (2)
Tips (10)
Keep a benzodiazepine like alprazolam on hand as an emergency trip abort tool when using ETH-LAD. Even just knowing you have one available provides psychological reassurance. It will not fully end the trip but significantly reduces intensity.
Use a milligram scale to weigh ETH-LAD if it comes as a powder. Eyeballing doses of potent psychedelics is irresponsible. A quality 0.001g scale costs under $30 and could prevent a seriously overwhelming experience.
ETH-LAD has a steep dose-response curve. The difference between a fun recreational experience and an overwhelming one can be as little as 25 micrograms. Most experienced users recommend staying at or below 150ug for a manageable experience, with 50-100ug being ideal for a first try.
ETH-LAD is considered by many to be the most visual lysergamide available. It produces intense, complex visual effects at lower doses than LSD, but with a heavier body load that some find uncomfortable, especially gastrointestinal effects.
ETH-LAD is notorious for causing nausea and stomach cramps, especially above 150ug. Having ginger tea or anti-nausea medication on hand is strongly recommended. Some users report that sublingual dosing reduces GI side effects compared to swallowing the tab.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid ETH-LAD and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
Community Discussions (5)
See Also
Same Class
References (5)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- PubChem: ETH-LAD
PubChem compound page for ETH-LAD (CID: 44457783)
pubchem - ETH-LAD - TripSit Factsheet
TripSit factsheet for ETH-LAD
tripsit - ETH-LAD - Wikipedia
Wikipedia article on ETH-LAD
wikipedia